- Products & Solutions
- FDA CLEARED
- About Us
- News & Events
- Contact BDC
- ADDITIONAL SITES
Tag: calprotectin
Health Canada Licence: 98903, Device class: 3 BÜHLMANN IBDoc® is not available for sale in the US. IBDoc® is the first self-testing application for fecal calprotectin in IBD patients that involves three easy steps. IBDoc® allows IBD patients convenient self-testing of fecal calprotectin. Teleconference Overview Goal of Discussion The goal was for Clinical Administrators and Clinical Users from
Continue Reading
BÜHLMANN fCAL® ELISA Citation Pavlidis, P. et al., 2016, Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease, Scandinavian Journal of Gastroenterology. PMID: 27400728 DOI: 10.1080/00365521.2016.1205128 Highlight from this Publication “The ΔFCAL could act as an ‘early warning’ to consider alternatives such as dose optimisation or another biologic with a different mode of action,
Continue Reading
BÜHLMANN fCAL® ELISA Citation Lasson, A. et al., 2014, Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of relapse: A prospective, randomized, controlled study, United European Gastroenterology Journal. PMID: 25653861 DOI: 10.1177/2050640614560785 Highlight from this Publication “In patients with UC, FC-guided dosing of the patient’s 5-ASA agent showed significantly lower relapse rates than
Continue Reading
In this "Summer Edition" we are pleased to announce the FDA 510 (k) clearance of the BÜHLMANN fCAL® ELISA. We make mention of upcoming meetings where you can find us such as American Association of Clinical Chemistry (AACC) and the Association of Medical Laboratory Immunologists (AMLI) annual meetings. Additionally, we share the exciting happenings pertaining to
Continue Reading
US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Pearl Avery, UK IBD Nurse of the year, shares her first experience using IBDoc® in clinical practice. She explains the study she published at ECCO 2018 in Vienna in this video. Highlight from this Poster "The BÜHLMANN IBDoc® adds
Continue Reading
BÜHLMANN fCAL® ELISA, accurate, precise, efficient calprotectin testing Health Canada License: 80726 US: BÜHLMANN fCAL® ELISA is FDA 510(k) cleared. For in vitro Diagnostic Use. Quantum Blue® platform offering rapid and quantitative results for fecal calprotectin, serum calprotectin, CRP, serum infliximab trough levels, and serum adalimumab trough levels (Additional trough level assays coming soon!) Health Canada Licenses: Quantum Blue® fCAL: 83477, Quantum Blue® fCAL extended: 100161 US: Research Use Only. Not
Continue Reading
BÜHLMANN fCAL® ELISA, an in vitro diagnostic assay intended for the quantitation of calprotectin in human stool, has received 510(k) clearance from the Food and Drug Administration (FDA) and is now commercially available in the US. Amherst NH, June 12, 2018: BÜHLMANN Laboratories AG, is proud to announce it has received United States Food and
Continue Reading
In this “Summer Edition” we are pleased to share the launch of the of Quantum Blue® Adalimumab assay as well as announce some recent enhancements to the Quantum Blue® Infliximab assay. We also make mention of the upcoming meetings…
Health Canada Licence: 98903, Device class: 3 IBDoc® is not available for sale in the US. Read perspectives and insights from a patient from the UK who has been using IBDoc® since last October and is trying this new tool to monitor his Crohn’s Disease. He has been documenting his experiences in a blog to share his
Continue Reading
